Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results In Phase 3 Trial

Wed, 29 Nov 2006 02:00 PM EST

... Dynavax Technologies Corporation (Nasdaq: DVAX) announced today statistically significant results from the primary endpoint analysis of a Phase 3 trial comparing HEPLISAV, its hepatitis B virus (HBV) vaccine, to GlaxoSmithKline's Engerix-B(R) vaccine in a difficult-to-immunize population of older adults. The primary endpoint is seroprotection four weeks after the third immunization. [click link for full article] ...